Cipla Gets New Price-Violation Notice From India Regulator
This article was originally published in PharmAsia News
Executive Summary
India's drug-pricing regulator served notice on Cipla for violating the rules in pricing its generic version of the antibiotic ciprofloxacin within the past nine months. At the same time, the Indian Supreme Court is considering another accusation that Cipla overcharged for a range of antibiotics and anti-asthma drugs four years ago. Cipla contends the new notice issued by the National Pharmaceutical Pricing Authority is covered by the pending court case brought by Cipla. Cipla contended in that case that NPPA's penalties were untenable and could not be sustained. (Click here for more